Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have been assigned an average rating of “Moderate Buy” from the twenty-seven ratings firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and twenty-two have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $542.00.

VRTX has been the subject of a number of research analyst reports. Morgan Stanley reissued an “overweight” rating and set a $570.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Sanford C. Bernstein restated an “outperform” rating and issued a $577.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Scotiabank lifted their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research report on Friday, February 13th. Canaccord Genuity Group boosted their price target on shares of Vertex Pharmaceuticals from $411.00 to $441.00 and gave the company a “hold” rating in a research note on Tuesday, February 17th. Finally, UBS Group increased their price objective on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Amit Sachdev sold 58,613 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $468.83, for a total transaction of $27,479,532.79. Following the completion of the transaction, the executive vice president directly owned 58,934 shares in the company, valued at $27,630,027.22. This trade represents a 49.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Charles F. Wagner, Jr. sold 14,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $456.00, for a total value of $6,384,000.00. Following the completion of the sale, the executive vice president owned 37,725 shares in the company, valued at $17,202,600. This represents a 27.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 168,937 shares of company stock valued at $77,879,922 over the last ninety days. 0.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Chesapeake Asset Management LLC raised its holdings in Vertex Pharmaceuticals by 110.0% in the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 33 shares in the last quarter. Motiv8 Investments LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $26,000. Access Investment Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $27,000. Colonial Trust Co SC lifted its position in shares of Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 38 shares during the last quarter. Finally, Swiss RE Ltd. acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth $28,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $496.83 on Monday. The company has a 50 day moving average price of $466.55 and a 200-day moving average price of $432.55. Vertex Pharmaceuticals has a 1-year low of $362.50 and a 1-year high of $519.68. The firm has a market cap of $126.21 billion, a price-to-earnings ratio of 32.41 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the prior year, the business posted $3.98 EPS. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Vertex Pharmaceuticals will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.